

6 December 2024

Syncona Limited

("Syncona" or the "Company")

Transaction in Own Shares

Syncona, a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science announces that, in accordance with the terms of its share buyback programme announced on 29 September 2023 (the "Share Buyback Programme"), the Company purchased the following number of its ordinary shares of no par value ("Ordinary Shares") each through Deutsche Numis.

| | |
|---|-----------------|
| Date of purchase: | 5 December 2024 |
| Aggregate number of Ordinary Shares purchased: | 150,000 |
| Lowest price paid per share (GBP): | 102.0133 |
| Highest price paid per share (GBP): | 102.0133 |
| Volume weighted average price paid per share (GBP): | 102.0133 |

The repurchased Ordinary Shares will be held by the Company in treasury. Following the purchase and settlement of these Ordinary Shares, the Company's issued ordinary share capital is 672,214,632 of which 43,310,638 Ordinary Shares will be held in treasury, which attract no voting rights. Therefore, the total voting rights in the Company will be 628,903,994. This figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 which forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Deutsche Numis as part of the Share Buyback Programme.

Individual information:

| Numbers of shares purchased | Transaction price (pence per share) | Time of transaction | Venue |
|-----------------------------|-------------------------------------|---------------------|-------|
| 150,000 | 102.0133 | 14:45:05 | XLON |

For further information, please contact:

Syncona Ltd
Natalie Garland-Collins / Fergus Witt
Tel: +44 (0) 20 3981 7912

Deutsche Numis
Nathan Brown
Freddie Barnfield
Tel: +44 (0) 20 7260 1000

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.

We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSTABFTMTJMBAI